文献速递消化道肿瘤放疗

直肠癌术前放化疗中45 Gy/55 Gy同步整合推量VMAT与常规放疗的倾向评分匹配比较

Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis.
PubMed 文献 · Radiat Oncol · 2017-09-21

本回顾性倾向评分匹配分析比较直肠癌术前放化疗中45 Gy/55 Gy分25次同步整合推量VMAT(SIB-VMAT)与三维适形放疗(3D-CRT)。匹配后SIB-VMAT组60例、3D-CRT组120例,两组病理完全缓解率、病理缓解率、无病生存和局部控制均无显著差异,SIB-VMAT组2例出现直肠膀胱瘘。

要点

  • SIB-VMAT组与3D-CRT组病理完全缓解率分别为17%与11%,差异无统计学意义(P=0.39)。
  • 两组病理缓解率分别为60%与44%(P=0.77),无病生存(P=0.32)和局部控制(P=0.52)亦无显著差异。
  • SIB-VMAT组明显的放射性晚期毒性为2例直肠膀胱瘘。

核心结论

  • SIB-VMAT可能是直肠癌术前放化疗有前景的方法。

研究设计与样本

  • 回顾性倾向评分匹配分析,按1:2匹配,从2005年至2015年145例患者中选取SIB-VMAT组60例和3D-CRT组120例。
  • SIB-VMAT方案为45 Gy/55 Gy分25次同步整合推量,同期化疗为口服尿嘧啶/替加氟加亚叶酸钙联合或不联合伊立替康。

主要发现

  • 两组病理完全缓解率分别为3D-CRT组11%和SIB-VMAT组17%(P=0.39)。
  • 两组病理缓解率分别为44%和60%(P=0.77)。
  • 两组无病生存(P=0.32)和局部控制(P=0.52)无显著差异。
  • 3D-CRT组36例(30%)和SIB-VMAT组19例(32%)出现复发。
  • SIB-VMAT组首次远处复发部位为肝6例和肺8例,明显放射性晚期毒性为直肠膀胱瘘2例。

关键数值与推荐

  • SIB-VMAT组病理完全缓解率17%,3D-CRT组11%(P=0.39)。
  • SIB-VMAT组病理缓解率60%,3D-CRT组44%(P=0.77)。
  • SIB-VMAT组无病生存P=0.32,局部控制P=0.52。
  • SIB-VMAT组复发19例(32%),3D-CRT组复发36例(30%)。
  • SIB-VMAT组明显放射性晚期毒性为直肠膀胱瘘2例。

临床怎么用

  • 对于直肠癌术前放化疗,SIB-VMAT可作为3D-CRT之外的备选放疗技术。
  • 采用SIB-VMAT时需关注直肠膀胱瘘等晚期毒性风险。

局限性

  • 本研究为回顾性分析,样本来自单中心2005年至2015年数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The aim of this retrospective study was to compare volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with three-dimensional conformal radiotherapy (3D-CRT) in preoperative chemoradiation for rectal cancers. METHODS AND MATERIALS: In the propensity score-matching analysis of 1:2, we selected 60 patients from the SIB-VMAT group and 120patients from the 3D-CRT group matched pairings out of 145 patients between 2005 and 2015. The regimen of concurrent combined chemotherapy was oral uracil/tegafur plus leucovorin with/without irinotecan. RESULTS: There were no significant differences between the two groups, in pathological complete response rates (pCR) (11% in the 3D-CRT group vs. 17% in the SIB-VMAT group, P = 0.39), pathological response rates (44% vs. 60%, P = 0.77), disease-free survival (P = 0.32), or local control (P = 0.52). The SIB-VMAT method marginally improved the rate of pathological grade 2-3 effects and the OS was significantly better in patients with grade 2-3 effects. Recurrence was seen in 36 patients (30%) in the 3D-CRT group and 19 patients (32%) in the SIB-VMAT group. The first distant recurrence site in the SIB-VMAT group was liver in 6 patients and lung in 8 patients. The obvious radiation-induced late toxicity in the SIB-VMAT group was recto-vesical fistula in two patients. CONCLUSIONS: The SIB-VMAT may be a promising method for preoperative CRT of rectal cancer.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yamashita H, Ishihara S, Nozawa H, et al. Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis. Radiat Oncol. 2017. PMID: 28934968. doi:10.1186/s13014-017-0894-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。